Safety, tolerability, and pharmacokinetics/-dynamics of the dipeptidyl peptidase 3-inhibiting antibody Procizumab in a first-in-human trial.

However, because these results did not reach statistical significance at later timepoints and were not found for the 6 mg/kg subgroup, a clear dose-dependency of these effects was not established.

also in 111,027 other papers